Form 4: Sionna Therapeutics Director Sells Shares Under 10b5-1 Plan

A director of Sionna Therapeutics, Peter A. Thompson, reported the sale of 108,073 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Peter A. Thompson, a Director of Sionna Therapeutics, Inc. (SION), reported the sale of common stock.
• The transactions were executed under a Rule 10b5-1(c) pre-arranged trading plan.
• On November 24, 2025, 94,583 shares were sold at a price of $44.54 per share.
• On November 25, 2025, 11,890 shares were sold at a price of $44.60 per share.
• On November 26, 2025, 1,600 shares were sold at a price of $44.49 per share.
• Following these transactions, the indirect beneficial ownership stands at 3,596,886 shares.
• The shares are held of record by OrbiMed Private Investments VIII, LP, and Mr. Thompson disclaims beneficial ownership except for his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider sales can sometimes be perceived negatively, the explicit mention of a 10b5-1 plan suggests these are pre-scheduled transactions rather than a reaction to new, adverse information. The sales represent a small fraction of the total indirect holdings.

Negatives

• A director sold a significant number of shares (108,073 shares in total) over three days.

Management Comments

• The Reporting Person, OrbiMed Advisors, and GP VIII disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any.

Industry Context

Insider sales, particularly those executed under a Rule 10b5-1 plan, are common in the biotechnology and pharmaceutical sectors as executives and directors manage their personal portfolios and liquidity. The sales by a director associated with a major institutional investor like OrbiMed are often part of a broader fund management strategy rather than a direct signal about the company's immediate prospects.

Related Party Transactions

• The shares are held indirectly by OrbiMed Private Investments VIII, LP, where the reporting person, Peter A. Thompson, is a member of OrbiMed Advisors LLC, which manages the fund. This represents a relationship between the director and the entity holding the shares.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even under a 10b5-1 plan, could be interpreted by some shareholders as a lack of confidence, though the pre-scheduled nature mitigates this. The overall impact is likely minimal given the context of a large institutional holder.

Key Dates

Recommendation

The reported sales by Director Peter A. Thompson are executed under a Rule 10b5-1 trading plan, indicating pre-scheduled transactions rather than a reaction to new company-specific information. While insider sales can sometimes signal a lack of confidence, the context of a 10b5-1 plan and the fact that the shares are held by a large institutional investor (OrbiMed) suggest these are likely part of routine portfolio management. The sales represent a relatively small portion of the total indirect holdings. Therefore, this filing alone does not provide a strong basis for a 'buy' or 'sell' recommendation, warranting a 'hold' position as investors should look for broader company fundamentals and market trends.

Keywords

Sionna Therapeutics, SION, Form 4, Insider Trading, Stock Sale, Director, Peter A. Thompson, OrbiMed, 10b5-1 Plan